Connect with us:     
Skip Navigation Links

Alan Menter, MD

 

 

Chief, Division of Dermatology

Baylor University Medical Center, Dallas TX

 

Clinical Professor of Dermatology

University of Texas, Southwestern Medical School

 

Director, Fellowship Program

Baylor Psoriasis Center, Dallas TX

 

Chair, Psoriasis Guidelines Committee, American Academy of Dermatology

 

Director, Dermatology Residency Program

Baylor University Medical Center

 

 

Contact Information  

3900 Junius Street Suite 125

Dallas TX 75246

 

(972) 386-7546 phone

(972) 661-3255 fax

 

E-mail General: amderm@gmail.com

E-mail Research: alanmresearch@gmail.com

 

 

Education                  

University of Witwatersrand, Johannesburg, South Africa

Medical Student (1959-1966)

                       

Internships

Department of Medicine, Johannesburg General Hospital (1967)

Department of Surgery, Johannesburg General Hospital (1967)                

Sr Intern, Medicine/Dermatology, Johannesburg Gen Hospital (1968)

                                               

Residency                    

Department of Dermatology, University of Pretoria

Pretoria (South Africa) General Hospital (1968-1971)

 

Fellowships                  

Guy’s Hospital, London, England (1971-1972)

St. John’s Hospital for Diseases of the Skin, London (1972-1973)

University of Texas Southwestern Medical School, Dallas TX (1977-1979)

 

 

Major Contributions to Science 

 

1.  First Gene Bank for Psoriasis. The National Psoriasis Gene Bank was originally based at the   clinic at Baylor, Dallas with Alan Menter, M.D. as Clinical Director. Families with psoriasis were assembled from all over the U.S. and blood samples taken to research the genetic basis for psoriasis. The first International Consortium meeting for the Genetics of Psoriasis was held in Dallas, sponsored by the National Psoriasis Foundation in 1994.

 

  • Tomforhde J, Silverman A, Barnes R, Fernandez-Vina MA, Young M, Lory D, Morris LF, Wuepper KD, Stastny P, Menter A, Bowcock A. Gene for familial psoriasis: susceptibility mapped to the distal end of human chromosome 17q. Science 1994;264:1141-45.

 

2.  Chair of the American Academy of Dermatology work group who developed the 6 AAD Guidelines of care for the management of psoriasis and psoriatic arthritis.

 

  • Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis.  Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50.
  • Gottlieb A, Korman NJ, Gordon K, Menter A, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-864.
  • Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009;60:643-59.
  • Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-85.
  • Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis.  Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010;62:114-35.
  • Menter A, Korman, NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011;65:137-74.     

 

3.  Dr. Alan Menter founded the International Psoriasis Council (IPC), an international organization dedicated to raising international consciousness and understanding of psoriasis as a serious immune-mediated disease with major quality of life implications. The organization is committed to advancing psoriasis research and treatment.  IPC provides a forum for collaboration, innovation and education among physicians, researchers and other medical professionals. Working together on the medical, social and economic aspects of psoriatic disease, IPC advances the standard of care Dr. Menter served as the initial President of IPC from 2004 until December 2010.  He currently serves on the board as the Immediate Past President.

 

4.  Dr. Menter is President of the 3rd World Psoriasis and Psoriatic Arthritis Conference to be held in Stockholm in 2012, organized by the International Federation of Psoriasis Associations (IFPA).

 

 

Research Grants 

 

Abbott Laboratories

Allergan, Inc.

Allermed

Amgen, Inc.

Asubio

Berlex, Inc.

Biogen Idec

Centocor, Inc.

Cephalon

Celgene

Collagenex Pharmaceuticals

CombinatoRx

Connetics Corporation

Corixa Corporation

Dermik Laboratories

Doak Dermatologics

Dow

DUSA

Eli Lilly

Ferndale Laboratories, Inc.

Fujisawa Healthcare, Inc.

Galderma

Genentech, Inc.

Genzyme

GlaxoSmithKline

Ligand Pharmaceuticals 

Medicis

MedImmune, Inc.

National Institutes of Health

National Psoriasis Foundation

Novartis Pharmaceuticals

Otsuka Pharmaceutical, Inc.

Pfizer

Promius Pharma

Protein Design Labs

QLT, USA

Regeneration Pharma AG

Roche Laboratories

Serono

Sinclair

Stiefel

Synta Pharma

Thermosurgery

3 M Pharmaceuticals

UCB

Vertex

Warner Chilcott

Wyeth

XOMA

Zars, Inc.

 

 

 

Key Publications (2009-2014)

 

1. Menter A, Abramovits W, Colon LE, Johnson LA, Gottschalk RW. Comparing Clobetasol, Propionate 0.05% Spray to Calcipotriene 0.005% Betamethasone Dipropionate 0.064% Ointment for the Treatment of Moderate to Severe Plaque Psoriasis J Dr Dermatol 2009 Jan;8(1):52-7

 

2. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Vorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; April;60(4):643-59

 

3. Ul Ain Kamili Q, Menter A. Psoriasis in the Pediatric Patient. Pediatric Society of Greater Dallas, First Quarter, Feb 2009, Pg 10-14

 

4. Boltan, LE, Menter A. Pustules and dystrophy of the nails. BUMC Proceedings - Dermatology Report, April 2009, 162-163

 

5. Farley E, Masrour S, McKey J, Menter A. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol 2009 Jun; 60(6):1024-31

 

6. Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young MA. Series of critically challenging case scenarios in moderate to severe psoriasis:A Delphi consensus approach. J Am Acad Dermatol July 2009; 61(1): S1,pg 1-46

 

7. Menter A, ul Ain Kamili Q, Farley E. Get under the skin – diagnosis and treatment of psoriasis and guidelines for specialists. Medical Economics, July 2009

 

8. Miner A, Menter A. The ethics of consulting with pharmaceutical companies. Clinics in Dermatology (2009) 27, 339-345

 

9. Larsen F, Menter A, Cockerell CJ, Wilcox BN. Verrucous linear (segmental) psoriasis of the right leg responding to radiation therapy. J Drugs Dermatol 2008 Oct;7(10):969-71

 

10. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Honigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD,Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. JEADV Oct 2009, vol 23, Supplmt 2

 

11. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R.  Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the  management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermato 2009 Sep;61(3):451-85

 

12. ul Ain Kamili Q, Menter A. Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy. J Drugs Dermatol Jan 2010;9(1):57-90

 

13. ul Ain Kamili Q, Menter A. Genetics of psoriasis and psoriatic arthritis. Psoriasis Forum, vol 15, No 1: 8-12

 

14. Tebbey P, Romiti R, Prens E, Menter A. The International Psoriasis Council Presents Top 2009 Research Articles. Psoriasis Forum, vol 15, No 2:24-32

 

15. Hollmig T, Menter A. Familial coincidence of hidradenitis suppurativa and steatocystoma Multiplex. Clin and Exp Dermatol 2009 Nov 3

 

16. Menter A, Korman NJ, Elmets CA, Feldman SR, et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009 Apr; 60  (4):643-59

 

17. Horn EJ, Chambers CD, Menter A, Kimabll A; IPC. Pregnancy outcomes in psoriasis: why do we know so little? J Am Acad Dermatol 2009 Aug;61(2):e5-8

 

18. Menter A, Korman NJ, Elmets CA, Feldman SR, et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009 Sep; 61(3):451-85

 

19. Menter A. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis. 2009 Oct;84(4 Suppl):14-24.

 

20. ul Ain Kamili, Menter A. Topical treatment of psoriasis. Curr Probl Dermatol. Karger 2009 vol 38, pp 37-58

 

21. Griffiths CEM, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A (ACCEPT study group). Comparison of ustekinumab and etanercept for moderate-to severe psoriasis. N Engl J Med Jan 14, 2010  362;2:118-28

 

22. Menter A, Augustin M, Signorovitch J, Yu A, Wu E, Gupta SR, Bao Y, Mulani P. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe  psoriasis: a randomized clinical trial. J Am Acad Dermatol 2010,e-pub March 8

 

23. Ryan C, Thrash B, Warren RB, Menter A. The use of ustekinumab in autoimmune diseases. Expert Opin Biol Ther 2010;10(4)

 

24. Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med and Surg March 2010; 29(1):10-15

 

25. Kavanaugh A, Menter A, Shen Y-K, Lee S, Mendelsohn A, Gottlieb A. Ustekinumab improves physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. Current Medical Research and opinion

 

26. Menter A, Gordon K, Leonardi C. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.. J Amer Acad Dermatol Sept 2010;63(3):

 

27. Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu M-C, Ortonne JP, Gordon K, Kimball A. Ustekinumab significantly improves symptoms of anxiety, depression, and skin- related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Amer Acad Dermatol Sept 2010;63(3)

 

28.              Zeichner J, Lebwohl M, Menter A, Bagel J, DelRosso J, Elewski B, Feldman S, Kircik L, Koo J, Stein Gold L, Tanghetti E. Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis, 2010 Sep;vol 86: 3S

 

29.              Menter A, Griffiths CEM, Tebbey PW, Horn EJ, Sterry W on behalf of the International Psoriasis Council. Exploring the association between cardiovascular and other disease related risk factors in the psoriasis population: the need for increased understanding across the medical community. JEADV 2010

 

30.              Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: Part I. J Amer Acad Dermatol Dec 2010 63(6):925-46

 

31.              Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: Part II. J Amer Acad Dermatol Dec 2010 63(6):949-72

 

32.              Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo YM, Lebwohl M, Leoanrdi CL, Lim HW, Van Vorhees AS, Beutner KR, Ryan C, Bhuhsan  Guidelines of care for the treatment of psoriasis and psoriatic arthritis: section 6. Case-based presentations and evidence-based conclusions. J Amer Acad Dermatol  July 2011 65(1):137-74

 

33.              Ryan C, Menter A, Warren RB. The latest advances in pharmacogenetics and pharmacogemonics in the treatment of psoriasis. Mol Diagn Ther. 2010 Apr 1;14(2):81-93.

 

34.              Menter A, Sofen H, Smith S, Papp K, Kempers S, Hudson CP, Colón LE, Johnson LA, Gottschalk R. An open-label, multicenter study of the efficacy and safety of an AM/PM treatment regimen with clobetasol propionate spray 0.05% and calcitriol ointment 3 microg/g in the management of plaque psoriasis. Cutis. 2011 Jul;88(1):46-51

 

35.              Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, Menter A. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011 Aug 24;306(8):864-71.

 

36.              van de Kerkhof P, Barker J, Griffiths CE, Menter A, Leonardi C, Young M, Kemeny L, Pincelli C, Bachelez H, Katsambas A, Ståhle M, Horn EJ, Sterry W; International Psoriasis Council. Improving clinical trial design in psoriasis: Perspectives from the global dermatology community. J Dermatolog Treat. 2011 Aug;22(4):187-93. Epub 2010 Oct 1.

 

37.              Joyce CE, Zhou X, Xia J, Ryan C, Thrash B, Menter A, Zhang W, Bowcock AM. Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet. 2011 Oct 15;20(20):4025-40. Epub 2011 Aug 1.

 

38.              Wittkowski KM, Leonardi C, Gottlieb A, Menter A, Krueger GG, Tebbey PW, Belasco J, Soltani-Arabshahi R, Gray J, Horn L, Krueger JG; International Psoriasis Council. Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis. PLoS One. 2011;6(6):e20279. Epub 2011 Jun 1.

 

39.              Kamili QU, Miner A, Hapa A, Menter A. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review. J Drugs Dermatol. 2011 May;10(5):539-44

 

40.              Farley E, Menter A. Psoriasis: comorbidities and associations. G Ital Dermatol Venereol. 2011 Feb;146(1):9-15. Review.

 

41.              Kimball AB, Gordon KB, Langley RG, Menter A, Perdok RJ, Valdes J; ABT-874 Study Investigators. Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. J Am Acad Dermatol. 2011 Feb;64(2):263-74. Epub 2010 Dec 9.

 

42.              Roberson ED, Liu Y, Ryan C, Joyce CE, Duan S, Cao L, Martin A, Liao W, Menter A, Bowcock AM A subset of methylated CpG sites differentiate psoriatic from normal skin.. J Invest Dermatol. 2012 Mar;132(3 Pt 1):583-92. doi: 10.1038/jid.2011.348. Epub 2011 Nov 10

 

43.              Hudson CP, Kempers S, Menter A, Papp K, Smith S, Sofen H, Colón LE, Johnson LA, Gottschalk R. An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis. Cutis. 2011 Oct;88(4):201-7.

 

44.              Strober BE, Armour K, Romiti R, Smith C, Tebbey PW, Menter A, Leonardi C. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol. 2012 Feb;66(2):317-22

 

45.              Abramson A, Menter A. An unusual facial ulcer. Proc (Baylor Univ Med Cent). 2012 Jan;25(1):85-6

 

46.              Dhaliwal S, Patel M, Menter A. Secondary syphilis and HIV. Proc (Baylor Univ Med Cent). 2012 Jan;25(1):87-9

 

47.              Heller MM, Wong JW, Nguyen TV, Lee ES, Bhutani T, Menter A, Koo JYQuality-of-life instruments: evaluation of the impact of psoriasis on patients.. Dermatol Clin. 2012 Apr;30(2):281-91, ix.

 

48.              Ryan C, Abramson A, Patel M, Menter A. Current investigational drugs in psoriasis. Expert Opin Invest Drugs. 2012 Apr;21(4):473-87

 

49.              Menter A. Response to the letter to editor re:”Methotrexate and psoriasis: consensus conference”. J Am Acad Dermatol. 2012 Apr;66(4):689; author reply 689-90

 

50.              Papp K, Menter A, Poulin Y, Gu Y, Sasso EH. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. J Eur Acad Dermatol Venereol. 2012 Mar 16. Epub ahead of print.

 

51.              Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012 Mar 29;366(13):1181-9

 

52.              Kragballe K, Menter A, Lebwohl M, Tebbey PW, van de Kerkhof PC, International Psoriasis Council. Long-term management of scalp psoriasis: perspectives from the international psoriasis council. J Dermatol treat 2012 Jun 5 (Epub ahead of print)

 

53.              Menter A. Clobetasol propionate spray 0.05% for the treatment of moderate to severe plaque psoriasis. Cutis. 2012 Feb;89(2):89-94

 

54.              Ryan C, Menter A. Psoriasis and cardiovascular disorders. G Ital Dermatol Venereol. 2012 Apr;147(2):179-87

 

55.              Wofford J, Patel M, Readinger A, Menter A. Widespread dermal ulcerations and bullae. Proc (Baylor Univ Med Cent). 2012 Apr;25(2):155-8

 

56.              Jordan CT, Cao L, Roberson ED, Pierson KC, Yang CF, Joyce CE, Ryan C, Duan S, Helms CA, Liu Y, Chen Y, McBride AA, Hwu WL, Wu JY, Chen YT, Menter A, Goldbach-Mansky R, Lowes MA, Bowcock AM. PSORS2 is due to mutations in CARD14. Am J Hum Genet. 2012 May 4;90(5):784-95

 

57.              Jordan CT, Cao L, Roberson ED, Duan S, Helms CA, Nair RP, Duffin KC, Stuart PE, Goldgar D, Hayashi G, Olfson EH, Feng BJ, Pullinger CR, Kane JP, Wise CA, Goldbach-Mansky R, Lowes MA, Peddle L, Chandran V, Liao W, Rahman P, Krueger GG, Gladman D, Elder JT, Menter A, Bowcock AM. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet. 2012 May 4;90(5):796-808.

 

58.               Menter A, Thrash B, Cherian C, Matherly LH, Wang L, Gangiee A, Morgan JR, MaedaDY, Schuler AD, Kahn SJ, Zebala JA. Intestinal transport of aminopterin enantiomers in dogs and humans with psoriasis is stereoselective: evidence for a mechanism involving the proton-coupled folate transporter. J Pharmacol Exp Ther. 2012 Sep;342(3):696-708.

 

59.              Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management. J Am Acad Dermatol. 2012 Jun 21. [Epub ahead of print]

 

60.              Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, Gupta P, Krishnaswami S, Tan H, Harness JA. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012 Sep;167(3):668-77

 

61.              Menter, A. Psoriasis and Psoriatic Arthritis: Similarities and Differences. Value-Base Care in Rheumatology, Sept 2012.

62.              Menter A, Caveney S, Gottschalk RW. Impact of Clobetasol Propionate 0.05% Spray on Health-Related Quality of Life in Patients with Plaque Psoriasis. J Dr Dermatol 2012 Nov; 11(11):1348-1353

 

63.              Lloyd P, Ryan C, Menter A. Psoriatic arthritis: a review. Arthritis. Vol 2012

 

64.              Corey K, Mattei P, Houston N, Tebbey PW, Menter A, van de Kerkhof PCM, Kimball AB. Psoriasis, a proof-of-principle condition for immune-mediated inflammatory disorders: perspectives toward optimal clinical trial design. Clin. Investing. 2012;2(7):671-78

 

65.              Paller A, Mercy K, Kwasny M, Choon S, Cordoro K, Girolomoni G, Menter A, Wynnis T, Mahoney A, Oostveen A, Marieke S. Association of Pediatric Psoriasis Severity with Excess and Central Adiposity: An International Cross-Sectional Study. Arch Dermatolo, Vol 148, Nov 2012

 

66.              Patel M, Day A, Warren R, Menter A. Emerging Therapies for the Treatment of Psoriasis, Dermatol Ther (Heidelb) 2012 Dec;2(1):16

 

67.              Menter A., Beyond the Skin: What Comorbidities Teach us About Understanding And Treating Psoriasis. Practical Dermatology, December 2012, 22-28.

 

68.              Mamolo C, Harness J, Tan H, Menter A. Tofacitinib (CP-690, 550) An Oral Janus Kinase Inhibitor, Improves Patient-Reported Outcomes in a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Moderate-to-Severe Psoriasis. J Eur Acad Dermatol Venereol, 2013 Jan 7 (Epub ahead of print)

 

69.              Mercy K, Kwasny M, Cordoro KM, Menter A, Tom WL, Korman N, Belazarian L, Armstrong AW, Levy ML, Paller AS. Clinical Manifestations of Pediatric Psoriasis: Results of a Multicenter Study in the United States. Pediatr Dermatol. 2013 Jan 30

 

70.              Menter A, Gold LS, Bukhalo M, Grekin S, Kempers S, Boyce BM, Ganslandt C, Villumsen J, Lebwohl M. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. J Drugs Dermatol. 2013 Jan; 12(1):92-8.

 

71.              Paller AS, Mercy K, Kwasny MJ, Choon SE, Cordoro KM, Girolomoni G, Menter A, Tom WL, Mahoney AM, Oostveen AM, Seyger MM. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol. 2013 Feb;149(2):166-76.

 

72.              Shah K, Boland R, Patel M, Thrash B, Menter A, Cutaneous Manifestations of Gastrointestinal Disease, Part I. JAAD, Vol. 68, Issue 2, Feb. 2013

 

73.              Thrash B, Patel M, Shah K, Boland R, Menter A, Cutaneous Manifestations of Gastrointestinal Disease, Part II. JAAD, Vol. 68, Issue 2, Feb. 2013

 

74.              Paller A, Mercy K, Kwasny M, Choon S, Cordoro K, Girolomoni G, Menter A, Wynnis T, Mahoney A, Oostveen A, Marieke S. Association of Pediatric Psoriasis Severity with Excess and Central Adiposity: An International Cross-Sectional Study. JAMA Dermatol/Vol. 149 (No.2), Feb 2013, 166-176

 

75.              Kimball AB, Pariser D, Yamauchi PS, Menter A, Teller CF, Shi Y, Yong M, Creamer K, Hooper M, Aras G, Kricorian G, Gelfand JM. OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. J Am Acad Dermatol, May 2013; 68(5): 756-64

 

76.              Mansouri B, Patel M, Menter A.Tumour necrosis factor-α inhibitor use in patients with psoriasis with organ transplantation. Br J Dermatol. 2013 Aug;169(2):481-3

 

77.              Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C, Schafer PH, Krueger JG. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol. 2013 Aug;12(8):888-97.

 

78.              Boehncke WH, Menter A. Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2013 Oct;14(5):377-88.

 

79.              Strober B, Buonanno M, Clark JD, Kawabata T, Tan H, Wolk R, Valdez H, Langley RG, Harness J, Menter A, Papp K. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol. 2013 Nov;169(5):992-9.

 

80.              Augustin M, Blome C, Costanzo A, Dauden E, Ferrandiz C, Girolomoni G, Gniadecki R, Iversen L, Menter A, Michaelis-Wittern K, Morita A, Nakagawa H, Reich K. Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): Development and Validation of a Tool for Assessment of Nail Psoriasis Outcomes. Br J Dermatol. 2013 Oct 11 doi: 10.1111/bjd.12664. [Epub ahead of print]

 

81.              Mansouri B, Patel M, Menter A. Biological therapies for psoriasis. Expert Opin Biol Ther. 2013 Dec;13(12):1715-30. doi: 10.1517/14712598.2013.853739. Epub 2013 Oct 28.

 

82.              Kivelevitch DN, Hebeler KR, Patel M, Menter A. Emerging topical treatments for psoriasis. Expert Opin Emerg Drugs. 2013 Dec; 18(4):523-32.

 

83.              Warren RB, Menter A. Dermatology: future therapeutic perspectives. Dermatol Ther (Heidelb). 2013 Dec;3(2):115-6.

 

84.              Ryan C, Korman NJ, Gelfand JM, Lim HW, Elmets CA, Feldman SR, Gottlieb AB, Koo JY, Lebwohl M, Leonardi CL, Van Voorhees AS, Bhushan R, Menter A. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol. 2014 Jan;70(1):146-67.

 

85.              Patel M, Menter A. Reply: Genital edema in Crohn's disease. J Am Acad Dermatol. 2014 Feb;7 0(2):385. doi: 10.1016/j.jaad.2013.10.026.

86.              Wofford J, Menter A. Ustekinumab for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2014 Feb;10(2):189-202.

 

87.                 Menter A, Papp KA, Tan H, Tyring S, Wolk R, Buonanno M. Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, on Clinical Signs of Moderate-to-Severe Plaque Psoriasis in Different Body Regions. J Drugs Dermatol. 2014 Mar 1;13(3):252-6.

 

88.                 Augustin, M., Blome, C., Costanzo, A., Dauden, E., Ferrandiz, C., Girolomoni, G., Gniadecki, R., Iversen, L., Menter, A., Michaelis-Wittern, K., Morita, A., Nakagawa, H. and Reich, K. (2014), Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. British Journal of Dermatology, 170: 591–598. doi: 10.1111/bjd.12664

 

89.                 Isabel Haugh, MB, BCh, BAO, Caitríona Ryan, MD, and Alan Menter, MD., Using Biologic Agents in Combination with Methotrexate in Psoriasis Therapy. The Dermatologist. 2014 Mar: 22(3):28-31.

 

90.                 Kivelevitch D, Mansouri B, Menter A., Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Biologics. 2014 Apr 17;8:169-182. eCollection 2014.

 

91.                 Mary E. Horner, Amanda K. Abramson, Richard B. Warren, Susan Swanson, M. Alan Menter. The spectrum of oculocutaneous disease: Part I. Infectious, inflammatory, and genetic causes of oculocutaneous disease. Journal of the American Academy of DermatologyVolume 70, Issue 5May 2014Pages 795.e1-795.e25

 

92.                 Antoinette Day, Amanda K. Abramson, Mahir Patel, Richard B. Warren, M. Alan Menter., The spectrum of oculocutaneous disease: Part II. Neoplastic and drug-related causes of oculocutaneous disease. Journal of the American Academy of DermatologyVolume 70, Issue 5May 2014Page 839.

 

 



Baylor Health Care System is located in Dallas, Texas